Gsk (GLAXF) EBT Margin (2016 - 2025)
Historic EBT Margin for Gsk (GLAXF) over the last 17 years, with Q3 2025 value amounting to 28.74%.
- Gsk's EBT Margin rose 279400.0% to 28.74% in Q3 2025 from the same period last year, while for Sep 2025 it was 23.71%, marking a year-over-year increase of 56700.0%. This contributed to the annual value of 11.08% for FY2024, which is 89100.0% down from last year.
- According to the latest figures from Q3 2025, Gsk's EBT Margin is 28.74%, which was up 279400.0% from 23.63% recorded in Q2 2025.
- In the past 5 years, Gsk's EBT Margin ranged from a high of 29.12% in Q1 2022 and a low of 0.8% during Q3 2024
- For the 5-year period, Gsk's EBT Margin averaged around 19.93%, with its median value being 20.06% (2021).
- Its EBT Margin has fluctuated over the past 5 years, first tumbled by -211800bps in 2024, then soared by 279400bps in 2025.
- Gsk's EBT Margin (Quarter) stood at 4.28% in 2021, then skyrocketed by 395bps to 21.18% in 2022, then skyrocketed by 30bps to 27.56% in 2023, then plummeted by -32bps to 18.69% in 2024, then soared by 54bps to 28.74% in 2025.
- Its EBT Margin stands at 28.74% for Q3 2025, versus 23.63% for Q2 2025 and 28.05% for Q1 2025.